Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
136 institutional managers report a position in Design Therapeutics, Inc. worth $649.1M between them, filed on form 13F for the quarter ending 2026-06-30. 19 of them hold 80% of it, the largest being SR One Capital Management, LP at 14.55%.
111 more managers in the register
19 managers hold 80% of the $649.1M institutional base. The other 117 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
DSGN (Design Therapeutics, Inc.) has 7 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
No intraday reading yet this session.
Design Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
via Baker Bros. Advisors LP, Logos Global Management LP, Trails Edge Capital Partners, LP +1 more · 5.97% of DSGN, 9.14% of FTH
via Logos Global Management LP, Frazier Life Sciences Management, L.P., Vivo Capital, LLC +2 more · 6.69% of DSGN, 6.40% of ACHV
via SR One Capital Management, LP, Vivo Capital, LLC, Logos Global Management LP +2 more · 14.55% of DSGN, 10.90% of ODTX
via Baker Bros. Advisors LP, Logos Global Management LP, Vivo Capital, LLC +1 more · 5.97% of DSGN, 6.79% of DBVT
via SR One Capital Management, LP · 14.55% of DSGN, 23.26% of MOBI
via Logos Global Management LP, Vivo Capital, LLC, Trails Edge Capital Partners, LP +1 more · 6.69% of DSGN, 7.77% of NERV
Managers holding a meaningful stake in DSGN also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.